RECRUITING

Different Types of Massage Therapy to Reduce Anxiety During Chemotherapy Infusion in Patients With Cancer

Conditions

Hematopoietic and Lymphatic System Neoplasm Malignant Solid Neoplasm

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This clinical trial tests how well different types of massage therapy works to reduce anxiety during chemotherapy infusions in patients with cancer. Many cancer patients experience moderate to severe anxiety and anxiety can worsen by the anticipation of medical procedures that patients have to receive, particularly chemotherapy. Massage therapy, as a complementary treatment, has shown promise in lessening both physical and psychological symptoms associated with cancer and its treatments. Research has also shown the benefits of massage therapy in reducing pain, stress, anxiety, nausea (upset stomach), fatigue (tiredness), and depression in cancer patients. Different types of massage therapy may potentially reduce some cancer patients' symptoms, enhance their treatment, and reduce treatment related side effects.

Official Title

Assessing the Feasibility of Different Types of Massage to Reduce Anxiety During Chemotherapy Infusion

Quick Facts

Study Start:2025-08-28

Study Completion:2026-11-28

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT07184294

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Participant must be 18 years of age or older at time of consent * The study is open to all participants regardless of gender, race, or ethnicity * Participants should have had at least 1 cycle of the chemotherapy regimen at the time of recruitment * Participant must have a baseline anxiety score \> 3 on the Visual Analog scale (VAS) * Scheduled for at least six more infusion sessions * Participant has had complete blood count (CBC) lab work completed in the past 24 hours	* Platelet count less than 20,000. Patients taking anticoagulants are not excluded, as the protocol for massage in infusion ensures that deep pressure massage is never performed, and patient's massage will not exceed a 3 on the Walton scale * Absolute neutrophil count (ANC) less than 500 * Patient has received radiation therapy to any of the targeted areas within the past 90 days * Any patient that is currently using a cold therapy device that would interfere with their ability to have a massage without removing the device (cold gloves, cold socks) * Had surgery on their foot, leg, head, neck, shoulder, hands, or arms within the past three months * Participant has rashes, open wounds, or any skin conditions that could be exacerbated by massage * Known allergies to creams, lotions, or any other substances that may be used during the massage therapy sessions * Ongoing uncontrolled active psychiatric condition that would interfere in the conduct of the study (e.g., mood disorders, anxiety, psychosis disorders, or substance use), as determined by the patient's primary cancer team * Participants with a known allergy to Bioton dual-purpose massage cream or any of its ingredients will be excluded from the study * In order to minimize undue influence and coercion, the study team will not personally solicit an employee for participation: An employee who is under the direct/indirect supervision of the principal investigator (PI)/a co-investigator/the study manager and a direct study team member * Pregnancy * Any participants with bone metastasis

Inclusion Criteria

Exclusion Criteria

* Participant must be 18 years of age or older at time of consent
* The study is open to all participants regardless of gender, race, or ethnicity
* Participants should have had at least 1 cycle of the chemotherapy regimen at the time of recruitment
* Participant must have a baseline anxiety score \> 3 on the Visual Analog scale (VAS)
* Scheduled for at least six more infusion sessions
* Participant has had complete blood count (CBC) lab work completed in the past 24 hours

* Platelet count less than 20,000. Patients taking anticoagulants are not excluded, as the protocol for massage in infusion ensures that deep pressure massage is never performed, and patient's massage will not exceed a 3 on the Walton scale
* Absolute neutrophil count (ANC) less than 500
* Patient has received radiation therapy to any of the targeted areas within the past 90 days
* Any patient that is currently using a cold therapy device that would interfere with their ability to have a massage without removing the device (cold gloves, cold socks)
* Had surgery on their foot, leg, head, neck, shoulder, hands, or arms within the past three months
* Participant has rashes, open wounds, or any skin conditions that could be exacerbated by massage
* Known allergies to creams, lotions, or any other substances that may be used during the massage therapy sessions
* Ongoing uncontrolled active psychiatric condition that would interfere in the conduct of the study (e.g., mood disorders, anxiety, psychosis disorders, or substance use), as determined by the patient's primary cancer team
* Participants with a known allergy to Bioton dual-purpose massage cream or any of its ingredients will be excluded from the study
* In order to minimize undue influence and coercion, the study team will not personally solicit an employee for participation: An employee who is under the direct/indirect supervision of the principal investigator (PI)/a co-investigator/the study manager and a direct study team member
* Pregnancy
* Any participants with bone metastasis

Contacts and Locations

Principal Investigator

Richard T Lee

PRINCIPAL_INVESTIGATOR

City of Hope Medical Center

Study Locations (Sites)

City of Hope at Irvine Lennar

Irvine, California, 92618

United States

Collaborators and Investigators

Sponsor: City of Hope Medical Center

Richard T Lee, PRINCIPAL_INVESTIGATOR, City of Hope Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-08-28

Study Completion Date2026-11-28

Study Record Updates

Study Start Date2025-08-28

Study Completion Date2026-11-28

Terms related to this study

Additional Relevant MeSH Terms

Hematopoietic and Lymphatic System Neoplasm
Malignant Solid Neoplasm